Tabernanthe iboga is a perennial rainforest shrub of the family Apocynaceae, native to the understory of Central West African forests. It grows slowly, sometimes taking decades to reach its full height of one to two meters. The leaves are small, dark green, and elliptical. The flowers are white to pink, tubular, and modest. The fruit is an orange, oval berry that splits to reveal seeds in reddish pulp.

None of this is what matters. What matters is underground.

The root bark, pale yellow when freshly peeled and drying to a fibrous tan, is where the plant concentrates its alkaloids. Fresh root bark has a faint, sharp smell, vegetal and slightly astringent. The taste is intensely bitter, among the most bitter plant materials people voluntarily consume. The bitterness is not incidental. It is how the Bwiti describe recognizing the plant's power: the more bitter, the more potent.

The bark is traditionally shaved or scraped from the root in long, thin strips. When dried and ground to powder, it takes on a pale ochre color. In ceremonial contexts, it may be chewed directly as shavings or consumed as ground powder mixed with water.

The name "iboga" is used broadly across the Bwiti tradition. Related terms include eboka and eboga. In French-speaking Central Africa, it is sometimes called bois sacré (sacred wood). "Ibogaine" refers specifically to the primary alkaloid, not the whole plant. The distinction matters: the root bark contains over a dozen alkaloids, and practitioners of Bwiti ceremony work with the whole bark, not a single isolated compound.

A pharmacological outlier

Most psychoactive substances work on one or two receptor systems. Ibogaine works on nearly all of them. This is not an exaggeration for effect. It is the central pharmacological fact about ibogaine, and it makes the compound genuinely difficult to classify.

The alkaloid family

Iboga root bark contains at least 12 indole alkaloids. The primary ones are:

• ●Ibogaine (12-methoxyibogamine), the most abundant and most studied, typically comprising 1-6% of dried root bark by weight
• ●Noribogaine (12-hydroxyibogamine), ibogaine's primary metabolite, formed in the liver and responsible for much of the prolonged aftereffect
• ●Tabernanthine, structurally similar, with overlapping but distinct receptor activity
• ●Ibogamine, present in smaller quantities
• ●Voacangine, found in related species and sometimes used as a precursor for semi-synthetic ibogaine

Traditional Bwiti practitioners do not isolate these compounds. They work with the full alkaloid profile of the root bark, and some practitioners believe the synergy between these molecules is essential to the experience.

How ibogaine works in the body

Ibogaine's receptor profile reads like a pharmacology textbook index. It interacts meaningfully with:

• ●NMDA glutamate receptors (antagonist), which may account for its dissociative and visionary properties
• ●Serotonin transporters (SERT inhibitor), contributing to mood effects
• ●Dopamine transporters (DAT inhibitor), relevant to its effects on reward circuitry and addiction
• ●Kappa-opioid receptors (agonist), linked to its dysphoric and visionary qualities
• ●Mu-opioid receptors (agonist), which may explain why it can interrupt opioid withdrawal
• ●Sigma-2 receptors, whose role is less understood
• ●Nicotinic acetylcholine receptors (antagonist), potentially relevant to its effects on tobacco craving
• ●Sodium and potassium ion channels (hERG channel blocker), which is the source of its cardiac risk

No other known psychoactive substance engages this many receptor systems simultaneously. This polypharmacology is likely why ibogaine produces such a distinctive, prolonged, and multidimensional experience.

The noribogaine factor

When ibogaine enters the body, the liver converts it to noribogaine (also called 12-hydroxyibogamine) through CYP2D6 metabolism. Noribogaine is itself psychoactive and has a much longer half-life than ibogaine, persisting in the body for days to weeks. Many researchers believe the sustained therapeutic effects attributed to ibogaine are actually mediated by noribogaine, which acts primarily on serotonin transporters and mu-opioid receptors.

This two-phase pharmacology, ibogaine followed by noribogaine, helps explain why the experience unfolds in distinct chapters: an acute visionary phase driven largely by ibogaine, followed by a prolonged reflective and restorative phase driven by noribogaine.

The cardiac question

Ibogaine blocks the hERG potassium channel, which regulates heart rhythm. This is the same channel affected by several pharmaceutical drugs that have been withdrawn from markets due to cardiac risk. Blockade of this channel can prolong the QT interval on an electrocardiogram, creating a window of vulnerability to potentially fatal arrhythmias. This is not a theoretical risk. Deaths have occurred, and cardiac screening before any ibogaine administration is considered essential by all serious practitioners and researchers.

Bwiti ceremony

The most established context for encountering iboga is the Bwiti tradition of Gabon, Cameroon, and the Republic of Congo. In a Bwiti initiation (ngoze), the candidate consumes large quantities of root bark over an extended period, sometimes 12-24 hours of intermittent ingestion, under the guidance of an nganga (spiritual leader). The ceremony involves music, particularly the mongongo mouth harp and the ngombi harp, which are considered essential to guiding the experience. The initiation can last three days. It is regarded as a death and rebirth, and the community that witnesses it plays a structural role.

Bwiti ceremony is not something one books online. It is embedded in a living cultural and spiritual tradition with its own protocols, hierarchies, and expectations.

Clinical ibogaine treatment

Since the 1960s, ibogaine has been explored in clinical and quasi-clinical settings for the interruption of substance dependence, particularly opioid addiction. Treatment typically involves purified ibogaine hydrochloride (HCl) administered in a medically monitored environment with cardiac monitoring equipment, IV access, and trained staff. Sessions take place in private clinics, most commonly in Mexico, New Zealand, Brazil, Costa Rica, and South Africa, where ibogaine is either legal or unregulated.

Clinical protocols include pre-treatment medical screening (ECG, liver function, electrolytes), monitored administration, and a recovery period of several days.

Underground and independent use

Some individuals obtain ibogaine or iboga root bark outside of both traditional and clinical contexts. This includes self-administered sessions, small group settings led by people with varying levels of training, and "sitter" arrangements. This context carries the highest risk, as cardiac monitoring and medical screening are often absent.

Microdosing

A smaller number of people consume very small amounts of iboga root bark on a regular basis, a practice sometimes associated with Bwiti tradition where small doses are taken as a stimulant and cognitive enhancer. This is distinct from the flood dose used in ceremony or addiction treatment.

The forests of the Congo Basin and coastal Gabon have held iboga for longer than anyone can document. The Pygmy peoples of the region are sometimes credited as the earliest to recognize the plant's properties, having observed animals behaving unusually after consuming the root. This knowledge, the story goes, was shared with Bantu-speaking peoples who developed it into the elaborate spiritual practice now known as Bwiti.

The Bwiti tradition is not a single practice but a family of related spiritual systems. Among the Mitsogo people of Gabon, Bwiti centers on ancestor veneration and divination. Among the Fang, it evolved into a syncretic practice incorporating elements of Christianity following colonial contact. In both cases, iboga sits at the center as the sacrament through which initiates access the spirit world, communicate with the dead, and understand their place in the community.

Colonial administrators and missionaries recognized iboga's cultural significance early. The French colonial government in Gabon attempted to suppress Bwiti practice in the early 20th century, viewing it as a threat to colonial order and Christian conversion. These efforts failed. Bwiti adapted, absorbed Christian imagery, and grew. By Gabonese independence in 1960, Bwiti was one of the country's most widespread spiritual practices. In 2000, the Gabonese government officially designated iboga as a national treasure and part of the country's cultural heritage.

The Western discovery

French and Belgian explorers first documented iboga in the mid-19th century. In 1901, the alkaloid ibogaine was isolated by Dybowski and Landrin. The pharmaceutical company CIBA marketed a product called "Lambarène" (an ibogaine extract) as a stimulant in France in the 1930s-1940s.

The modern addiction treatment story begins in 1962, when Howard Lotsof, a young heroin addict in New York, took ibogaine recreationally and discovered that his opioid withdrawal symptoms and craving had vanished. Lotsof spent the rest of his life advocating for ibogaine as an addiction treatment, obtaining patents for its use and founding the Global Ibogaine Therapy Alliance. His early observations were later supported by animal research showing that ibogaine reduces self-administration of morphine, cocaine, alcohol, and nicotine in rodent models.

Despite promising early results, ibogaine has never completed the full FDA approval process. Its cardiac risks, the length and intensity of the experience, and the difficulty of conducting placebo-controlled trials with a substance that produces unmistakable effects have all been barriers. Research continues, with synthetic analogs like 18-MC and tabernanthalog being developed to retain ibogaine's anti-addictive properties while reducing cardiac risk.

A plant under pressure

The growing global demand for ibogaine, driven largely by the addiction treatment movement, has placed enormous pressure on wild iboga populations. The plant grows slowly, and the root bark harvest is destructive. This has created a conservation crisis, particularly in Gabon, which is explored in detail in the Ethics and Ecology section.

Iboga and ibogaine carry real, documented, fatal risks. This section is not a formality. Multiple deaths have been attributed to ibogaine, and understanding the risk landscape is essential for anyone considering, researching, or working with this substance.

Cardiac risk

Ibogaine prolongs the QT interval by blocking the hERG potassium channel in the heart. A prolonged QT interval can trigger a type of arrhythmia called Torsades de Pointes, which can degenerate into ventricular fibrillation and death. This is the primary cause of ibogaine-related fatalities.

Risk factors that increase cardiac danger include:

• ●Pre-existing heart conditions (especially long QT syndrome, structural heart disease, or arrhythmia history)
• ●Electrolyte imbalances (low potassium or magnesium)
• ●Concurrent use of other QT-prolonging medications (methadone, certain antibiotics, antipsychotics, antidepressants)
• ●Liver impairment (slows ibogaine metabolism, increasing exposure duration)
• ●Advanced age

Cardiac monitoring (continuous ECG) throughout the experience is considered the minimum standard of care by researchers and responsible clinicians. A baseline ECG and metabolic panel before administration is essential.

Physical stress

The 24-36 hour duration places significant demands on the body. Dehydration, inability to eat, prolonged immobility, and disrupted thermoregulation all compound the physical burden. People with compromised physical health face elevated risks.

Liver toxicity

Ibogaine is metabolized by the liver, and there are reports of liver stress in some individuals. Pre-existing liver disease is a contraindication.

Psychological risks

The intensity and duration of the experience can be psychologically destabilizing, particularly for individuals with a history of psychosis, severe PTSD, or bipolar disorder. The visionary content can include deeply disturbing material. The extended duration means there is no option to "wait it out" quickly.

Drug interactions

Ibogaine interacts dangerously with numerous substances:

• ●Opioids: While ibogaine is studied for opioid addiction, active opioid use during ibogaine administration is dangerous. Timing of last opioid dose is critical.
• ●Stimulants: Cocaine and amphetamines increase cardiac risk.
• ●SSRIs and SNRIs: Serotonergic interactions are possible given ibogaine's SERT activity.
• ●Methadone: Especially dangerous due to additive QT prolongation.
• ●Benzodiazepines: May be used cautiously in clinical settings but require careful management.
• ●Alcohol: Should be avoided.

Populations requiring extreme caution

• ●Anyone with cardiac history or family history of sudden cardiac death
• ●People with liver disease
• ●People with seizure disorders
• ●Pregnant or nursing individuals
• ●People taking psychiatric medications (requires careful tapering under medical guidance)
• ●Elderly individuals

The fatality record

Estimates vary, but published case reports and tracking by organizations like the Global Ibogaine Therapy Alliance document several dozen deaths associated with ibogaine since the 1990s. Many occurred in unmonitored settings. Some occurred in clinical settings with apparently adequate screening. The true number is likely higher than published reports indicate. This fatality rate, while low relative to the number of administrations, is higher than for most other psychoactive substances used in similar contexts.

Integration after iboga is not a weekend project. The experience is so long and so dense with material that making sense of it may take weeks or months. People who expect immediate transformation often find that the real work begins after the alkaloids have cleared.

The first days

The 3-7 days following an iboga experience are often characterized by physical fatigue, emotional sensitivity, vivid dreams, and a sense of openness that can feel both fragile and valuable. Sleep patterns may be disrupted. Appetite returns slowly. Many people describe a feeling of having been "taken apart and put back together," and the reassembly process is not instantaneous.

During this period, gentle physical activity, adequate nutrition, rest, and minimal stimulation are widely recommended. Screens, social obligations, and demanding environments can feel overwhelming.

The window

Noribogaine's long presence in the body creates what some researchers and practitioners describe as a "window of opportunity," a period of weeks during which old habits feel less compelling, emotional patterns are more visible, and new behaviors may be easier to establish. This window is not permanent. Without deliberate effort, old patterns tend to reassert themselves.

Approaches to integration

There is no single correct method. Approaches that people report finding helpful include:

• ●Journaling: Writing down the visions, insights, and emotional content of the experience before it fades
• ●Therapy: Working with a therapist (ideally one familiar with psychedelic experiences) to process what emerged
• ●Community: Connecting with others who have gone through similar experiences, whether through Bwiti community, ibogaine treatment alumni networks, or peer support groups
• ●Body practices: Gentle yoga, walking in nature, breathing exercises, or bodywork to help process somatic material
• ●Lifestyle changes: Using the window period to establish new routines, end harmful relationships, or begin recovery programs

A caution about expectations

Iboga has a reputation in some circles as a "one-session cure" for addiction. This framing is misleading. While ibogaine can interrupt acute withdrawal and reduce craving, sustained recovery requires ongoing support, behavioral change, and often continued therapeutic work. The experience may open a door, but walking through it is the person's responsibility.

A conservation crisis

Iboga is in trouble. The plant grows slowly in the wild, taking 5-7 years to produce a root system substantial enough to harvest, and the harvest itself is often lethal to the plant. As global demand for ibogaine has increased, driven primarily by the addiction treatment movement, wild iboga populations in Gabon have declined significantly.

In 2019, Gabon's government took the unprecedented step of banning the export of iboga. The decision reflected both ecological concern and cultural protectionism. Gabon sees iboga as a national heritage, not a commodity for foreign pharmaceutical development.

Despite the ban, illegal harvesting and smuggling continue. The economic incentives are powerful: iboga root bark commands high prices internationally, and rural communities in Gabon face poverty that makes enforcement difficult.

Sustainability alternatives

Several approaches are being explored to reduce pressure on wild populations:

• ●Cultivation programs: Efforts to farm iboga commercially, though the slow growth rate makes this economically challenging
• ●Voacanga africana: A related tree whose bark contains voacangine, which can be semi-synthetically converted to ibogaine. This is currently the primary commercial source of pharmaceutical-grade ibogaine
• ●Total synthesis: Chemical synthesis of ibogaine from non-botanical precursors, though this remains expensive
• ●Analog development: Compounds like 18-MC (18-methoxycoronaridine), tabernanthalog, and oxa-ibogaine are being developed to replicate ibogaine's therapeutic effects without requiring the plant at all

Cultural sovereignty

The relationship between Western ibogaine clinics and Gabonese Bwiti tradition raises genuine questions of cultural appropriation. The knowledge that iboga has anti-addictive properties comes directly from traditional use. Bwiti practitioners have worked with this plant for centuries. The global ibogaine treatment industry profits from this knowledge while the communities that developed it often see little benefit.

Some organizations, including the Global Ibogaine Therapy Alliance, have worked to build bridges between Western researchers and Bwiti communities. Others argue that reciprocity programs and benefit-sharing agreements are necessary before the international ibogaine community can claim ethical standing.

The question is not simple. Bwiti is a living tradition, not a museum exhibit, and its practitioners have their own views on how iboga should be shared with the world. These views are not uniform. Some Bwiti leaders welcome international interest. Others view it as extraction.

The legal patchwork

Ibogaine's legal status varies dramatically by country. It is a Schedule I controlled substance in the United States, Belgium, and several other nations. It is unregulated in Mexico, Brazil, Costa Rica, and much of Africa. New Zealand has a unique regulatory framework allowing ibogaine to be prescribed by licensed medical practitioners. This uneven landscape pushes treatment seekers toward countries with permissive regulations, creating a medical tourism industry with highly variable standards of care.